首页> 外文期刊>Poiesis & praxis >Genetic tests in the insurance system: criteria for a moral evaluation
【24h】

Genetic tests in the insurance system: criteria for a moral evaluation

机译:保险系统中的基因检测:道德评估的标准

获取原文
获取原文并翻译 | 示例
       

摘要

An increasing number of genetic tests are available as an early spin-off from human genetic research. Beyond their application in the context of medical diagnosis there are other possible domains of use: e.g. in the testing of individuals asking for life or health insurance. It is claimed that individuals with an increased genetic risk might have to pay higher premiums or, worse, might be unable to obtain insurance coverage at all. The main question discussed in this paper will be whether there is a right to health and/or life insurance coverage without prior genetic testing. The legal regulations of the use of genetic tests in the insurance system are various. While some countries in principle permit the use of (some) genetic tests for the calculation of actuarial risks, others banned genetic tests for non-medical uses; still other countries have not made any explicit provisions up to now. In the face of the attempted harmonisation of legal systems, as well as an increasing commercialisation of the international market for genetic tests, which neglects national borders, providing criteria for a moral evaluation of this issue appears to be a timely and urgent task. The view defended in this paper is that a right to health insurance without genetic testing is legitimised, insofar as health insurance belongs to the provision of elementary requirements, and insofar as the latter is everybody's moral right. On the other hand, it is implausible to postulate a right to life insurance without genetic testing - as long as life insurance is understood to be a part of one's provision of supplementary requirements.
机译:作为人类基因研究的早期衍生产品,越来越多的基因测试可提供。除了它们在医学诊断中的应用外,还有其他可能的使用领域:在测试要求人寿或健康保险的个人中。据称,遗传风险增加的个人可能必须支付更高的保费,或者更糟的是,根本无法获得保险。本文讨论的主要问题将是,如果没有事先进行基因测试,是否有享受健康和/或人寿保险的权利。在保险系统中使用基因检测的法律规定多种多样。虽然一些国家原则上允许使用(一些)基因测试来计算精算风险,但其他一些国家则禁止将基因测试用于非医疗用途;到目前为止,其他国家尚未做出任何明确规定。面对统一法律制度的企图,以及忽视国界的基因检测国际市场日益商业化,为这一问题进行道德评估的标准似乎是一项及时而紧迫的任务。本文主张的观点是,只要健康保险属于基本要求的规定,而后者是每个人的精神权利,则不进行基因检测的健康保险权利是合法的。另一方面,假定没有基因检测的人寿保险权利是不可信的-只要人们认为人寿保险是其补充要求中的一部分即可。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号